Evidence map›Paper›PMID 40760321›Full record

Trial reportAnnals of surgical oncology2026

Comparing Regional Saturation Biopsy and Targeted Biopsy: Is Perilesional Biopsy Necessary for High-Prostate-Specific Antigen Patients?

Mingzhe Chen, Shanqi Guo, Baojie Ma, Nan Wang, Jing Tian, Liwei Liu, Ranlu Liu, Yong Wang, Yong Xu, Xingkang Jiang

Erratum issuedAbstract readRandomized Controlled TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Mingzhe Chen *Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.ORCID http://orcid.org/0009-0002-5239-9933
Shanqi Guo *Department of Oncology, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.ORCID http://orcid.org/0000-0002-8385-4567
Baojie Ma *Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Nan WangTianjin Cancer Institute, Tianjin's Clinical Research Center for Cancer, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Jing TianDepartment of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Liwei LiuDepartment of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Ranlu LiuDepartment of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. liuranlu1976@126.com.ORCID http://orcid.org/0000-0003-0425-4430
Yong WangDepartment of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Yong XuDepartment of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.ORCID http://orcid.org/0000-0002-8060-3498
Xingkang JiangDepartment of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. jiangx@tmu.edu.cn.ORCID http://orcid.org/0000-0003-3084-1655

Funding

Second Hospital of Tianjin Medical University MNRC202312Second Hospital of Tianjin Medical University MYSRC202306Tianjin Science and Technology Project 21ZXJBSY00090Tianjin Science and Technology Project 24JCYBJC01040Tianjin Science and Technology Project KJ20169
6 · The paper itself

Abstract

backgroundPrevious studies have indicated that regional saturation prostate biopsy (RSB) is more effective than targeted biopsy (TB) or systematic biopsy (SB) for patients with prostate-specific antigen (PSA) levels between 4 and 20 ng/mL. However, its efficacy in patients with PSA levels ≥ 20 ng/mL remains unclear. PATIENTS AND

methodsIn this prospective, single-center, randomized controlled trial, we enrolled patients with PSA levels greater than 20 ng/mL and suspicious magnetic resonance imaging (MRI) findings from January 2021 to August 2023. The participants were randomized to undergo RSB or TB, and SB was also performed. The primary endpoint was the detection rate of clinically significant prostate cancer (csPCa), defined as an International Society of Urological Pathology (ISUP) grade ≥ 2.

resultsRSB detected csPCa more frequently than did TB (90.2% versus 82.9%, p = 0.01) and SB (90.2% versus 82.5%, p = 0.01). Supplementary SB did not increase csPCa detection in the RSB group but did increase it in the TB group. Subgroup analysis revealed that RSB was particularly effective for patients with PSA levels between 20 and 50 ng/mL, prostate imaging-reporting and data system (PI-RADS) score of 3 lesions, prostate volume (PV) > 45 mL, and PSA density (PSAD) < 1.0 ng/mL/cc. However, the single-center design limits the generalizability of our findings.

conclusionsOur trial suggests that RSB is superior to TB in detecting significant prostate cancers among patients with high PSA levels (≥ 20 ng/mL). Notably, perilesional biopsy is crucial for those with PSA levels between 20 and 50 ng/mL, larger PV, low PSAD, and low PI-RADS scores, enhancing csPCa detection.

Indexed as

Image-Guided BiopsyProstateProstate-Specific AntigenProstatic NeoplasmsAgedFollow-Up StudiesHumansMagnetic Resonance ImagingMaleMiddle AgedPrognosisProspective StudiesProstate-Specific AntigenPerilesional biopsyProstate biopsyProstatic neoplasmsRegional saturation biopsySystematic biopsyTargeted biopsy

Identifiers

PMID40760321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.